Skip to content
PepGen Logo

PepGen: 2024 Q1 Advocacy Newsletter

April 19, 2024

PepGen has released their Q1 Advocacy Newsletter for 2024, including an update for the Canadian Duchenne muscular dystrophy community regarding the CONNECT1-ED051 clinical trial.


  • January 8: PepGen announced that they successfully dosed the first person in the CONNECT1-EDO51 study.
  • March 13: PepGen received United States FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51

Get the full update from PepGen and read more about their ongoing enrollment for the CONNECT1-ED051 clinical trial:

PepGen is actively enrolling participants for their clinical trial testing whether their investigational drug, PGN-EDO51, is safe and tolerable for boys and men with Duchenne. Canadian locations:

  • Fredericton, New Brunswick – Stan Cassidy Centre for Rehabilitation
  • Ottawa, Ontario – Children’s Hospital of Eastern Ontario (CHEO)
  • Toronto, Ontario – The Hospital for Sick Children (SickKids)
  • Québec, Quebec – CHU de Québec

For information on clinical trial locations, please contact Patient Advocacy.

Related Articles